Karen Blyth

List of Publications by Year
in descending order

107 papers	8,180 citations	50276 46 h-index	51608 86 g-index
127 all docs	127 docs citations	127 times ranked	13565 citing authors

#	Article	IF	Citations
1	p53-mediated redox control promotes liver regeneration and maintains liver function in response to CCl4. Cell Death and Differentiation, 2022, 29, 514-526.	11.2	13
2	A noninvasive iRFP713 p53 reporter reveals dynamic p53 activity in response to irradiation and liver regeneration in vivo. Science Signaling, 2022, 15, eabd9099.	3.6	4
3	Dual G9A/EZH2 Inhibition Stimulates Antitumor Immune Response in Ovarian High-Grade Serous Carcinoma. Molecular Cancer Therapeutics, 2022, 21, 522-534.	4.1	20
4	Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics. Cell Death and Differentiation, 2022, 29, 2089-2104.	11.2	10
5	Selection of established tumour cells through narrow diameter micropores enriches for elevated Ras/Raf/MEK/ERK MAPK signalling and enhanced tumour growth. Small GTPases, 2021, 12, 294-310.	1.6	7
6	NUPR1 protects liver from lipotoxic injury by improving the endoplasmic reticulum stress response. FASEB Journal, 2021, 35, e21395.	0.5	4
7	An ARF GTPase module promoting invasion and metastasis through regulating phosphoinositide metabolism. Nature Communications, 2021, 12, 1623.	12.8	18
8	Breast cancer dependence on MCL-1 is due to its canonical anti-apoptotic function. Cell Death and Differentiation, 2021, 28, 2589-2600.	11.2	28
9	Immune-regulated IDO1-dependent tryptophan metabolism is source of one-carbon units for pancreatic cancer and stellate cells. Molecular Cell, 2021, 81, 2290-2302.e7.	9.7	54
10	MICAL1 regulates actin cytoskeleton organization, directional cell migration and the growth of human breast cancer cells as orthotopic xenograft tumours. Cancer Letters, 2021, 519, 226-236.	7.2	10
11	BRD4-mediated repression of p53 is a target for combination therapy in AML. Nature Communications, 2021, 12, 241.	12.8	43
12	Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy. Nature Communications, 2021, 12, 366.	12.8	138
13	Differential requirements for MDM2 E3 activity during embryogenesis and in adult mice. Genes and Development, 2021, 35, 117-132.	5.9	6
14	Apoptotic stress-induced FGF signalling promotes non-cell autonomous resistance to cell death. Nature Communications, 2021, 12, 6572.	12.8	28
15	Loss of RAF kinase inhibitor protein is involved in myelomonocytic differentiation and aggravates RAS-driven myeloid leukemogenesis. Haematologica, 2020, 105, 375-386.	3.5	11
16	BRF1 accelerates prostate tumourigenesis and perturbs immune infiltration. Oncogene, 2020, 39, 1797-1806.	5.9	10
17	Polyamine pathway activity promotes cysteine essentiality in cancer cells. Nature Metabolism, 2020, 2, 1062-1076.	11.9	35
18	Impact of Formate Supplementation on Body Weight and Plasma Amino Acids. Nutrients, 2020, 12, 2181.	4.1	3

#	Article	IF	Citations
19	Formate induces a metabolic switch in nucleotide and energy metabolism. Cell Death and Disease, 2020, 11, 310.	6.3	31
20	The MSPâ€RON axis stimulates cancer cell growth in models of triple negative breast cancer. Molecular Oncology, 2020, 14, 1868-1880.	4.6	15
21	Somatic base editing to model oncogenic drivers in breast cancer. Lab Animal, 2020, 49, 115-116.	0.4	1
22	DNMT3B Oncogenic Activity in Human Intestinal Cancer Is Not Linked to CIMP or BRAFV600E Mutation. IScience, 2020, 23, 100838.	4.1	4
23	Dynamic ROS Control by TIGAR Regulates the Initiation and Progression of Pancreatic Cancer. Cancer Cell, 2020, 37, 168-182.e4.	16.8	159
24	Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses. Cell Reports, 2020, 30, 481-496.e6.	6.4	111
25	A role for CBFÎ² in maintaining the metastatic phenotype of breast cancer cells. Oncogene, 2020, 39, 2624-2637.	5.9	11
26	RUNX1 Is a Driver of Renal Cell Carcinoma Correlating with Clinical Outcome. Cancer Research, 2020, 80, 2325-2339.	0.9	21
27	RUNX1 Dosage in Development and Cancer. Molecules and Cells, 2020, 43, 126-138.	2.6	16
28	Complex Interplay between the RUNX Transcription Factors and Wnt/Î²-Catenin Pathway in Cancer: A Tango in the Night. Molecules and Cells, 2020, 43, 188-197.	2.6	15
29	RUNX1 marks a luminal castration-resistant lineage established at the onset of prostate development. ELife, 2020, 9, .	6.0	34
30	Increasing the bactofection capacity of a mammalian expression vector by removal of the f1 ori. Cancer Gene Therapy, 2019, 26, 183-194.	4.6	11
31	Migration through physical constraints is enabled by MAPK-induced cell softening via actin cytoskeleton re-organization. Journal of Cell Science, 2019, 132, .	2.0	37
32	Brf1 loss and not overexpression disrupts tissues homeostasis in the intestine, liver and pancreas. Cell Death and Differentiation, 2019, 26, 2535-2550.	11.2	10
33	Improving the metabolic fidelity of cancer models with a physiological cell culture medium. Science Advances, 2019, 5, eaau7314.	10.3	249
34	Increased formate overflow is a hallmark of oxidative cancer. Nature Communications, 2018, 9, 1368.	12.8	90
35	MCL-1 is a prognostic indicator and drug target in breast cancer. Cell Death and Disease, 2018, 9, 19.	6.3	134
36	Runx1 Deficiency Protects Against Adverse Cardiac Remodeling After Myocardial Infarction. Circulation, 2018, 137, 57-70.	1.6	65

#	Article	IF	Citations
37	Mutant p53s generate pro-invasive niches by influencing exosome podocalyxin levels. Nature Communications, 2018, 9, 5069.	12.8	91
38	BET Inhibitors Potentiate Activation of p53 and Killing of AML By MDM2 Inhibitors â€” a Candidate Combination Therapy. Blood, 2018, 132, 3912-3912.	1.4	2
39	Acetate Recapturing by Nuclear Acetyl-CoA Synthetase 2 Prevents Loss of Histone Acetylation during Oxygen and Serum Limitation. Cell Reports, 2017, 18, 647-658.	6.4	202
40	Secreted CLIC3 drives cancer progression through its glutathione-dependent oxidoreductase activity. Nature Communications, 2017, 8, 14206.	12.8	81
41	Modulating the therapeutic response of tumours to dietary serine and glycine starvation. Nature, 2017, 544, 372-376.	27.8	449
42	Development of an inducible mouse model of iRFP713 to track recombinase activity and tumour development in vivo. Scientific Reports, 2017, 7, 1837.	3.3	19
43	Increased T-cell Infiltration Elicited by <i>Erk5</i> Deletion in a <i>Pten</i>-Deficient Mouse Model of Prostate Carcinogenesis. Cancer Research, 2017, 77, 3158-3168.	0.9	20
44	Runx Genes in Breast Cancer and the Mammary Lineage. Advances in Experimental Medicine and Biology, 2017, 962, 353-368.	1.6	16
45	<i>In vivo</i>models in breast cancer research: progress, challenges and future directions. DMM Disease Models and Mechanisms, 2017, 10, 359-371.	2.4	131
46	Role of innate immune responses in the effectiveness of oncolytic adenovirus as an anticancer agent. Lancet, The, 2017, 389, S61.	13.7	0
47	The enigmatic role of <scp>RUNX</scp>1 in femaleâ€related cancers â€" current knowledge & future perspectives. FEBS Journal, 2017, 284, 2345-2362.	4.7	22
48	RIPK3 promotes adenovirus type 5 activity. Cell Death and Disease, 2017, 8, 3206.	6.3	16
49	CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity. Scientific Reports, 2017, 7, 16827.	3.3	68
50	Oncogene-Expressing Senescent Melanocytes Up-Regulate MHC Class II, aÂCandidate Melanoma Suppressor Function. Journal of Investigative Dermatology, 2017, 137, 2197-2207.	0.7	30
51	Tumor matrix stiffness promotes metastatic cancer cell interaction with the endothelium. EMBO Journal, 2017, 36, 2373-2389.	7.8	144
52	Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. Nature Communications, 2017, 8, 2255.	12.8	65
53	Mitochondrial permeabilization engages NF-ÎºB-dependent anti-tumour activity under caspaseÂdeficiency. Nature Cell Biology, 2017, 19, 1116-1129.	10.3	181
54	The Sharing Experimental Animal Resources, Coordinating Holdings (SEARCH) Framework: Encouraging Reduction, Replacement, and Refinement in Animal Research. PLoS Biology, 2017, 15, e2000719.	5.6	18

#	Article	IF	Citations
55	SEARCHBreast: a new resource to locate and share surplus archival material from breast cancer animal models to help address the 3Rs. Breast Cancer Research and Treatment, 2016, 156, 447-452.	2.5	11
56	Condensin II mutation causes T-cell lymphoma through tissue-specific genome instability. Genes and Development, 2016, 30, 2173-2186.	5.9	41
57	The initiator methionine tRNA drives cell migration and invasion leading to increased metastatic potential in melanoma. Biology Open, 2016, 5, 1371-1379.	1.2	44
58	CRISPR/Cas9-Mediated <i>Trp53</i> and <i>Brca2</i> Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma. Cancer Research, 2016, 76, 6118-6129.	0.9	145
59	SEARCHBreast: An online resource designed to increase the efficiency of using materials derived from breast cancer studies in animals. Journal of Pathology, 2016, 240, 120-120.	4.5	0
60	Serine one-carbon catabolism with formate overflow. Science Advances, 2016, 2, e1601273.	10.3	128
61	SEARCHBreast: a new online resource to make surplus material from in vivo models of breast cancer visible and accessible to researchers. Breast Cancer Research, 2016, 18, 59.	5.0	2
62	Introducing SEARCHBreast: a virtual resource to facilitate sharing of surplus animal material developed for breast cancer research. Npj Breast Cancer, 2016, 2, 16020.	5.2	1
63	In-Depth Proteomics Identifies a Role for Autophagy in Controlling Reactive Oxygen Species Mediated Endothelial Permeability. Journal of Proteome Research, 2016, 15, 2187-2197.	3.7	22
64	The Initiator Methionine tRNA Drives Secretion of Type II Collagen from Stromal Fibroblasts to Promote Tumor Growth and Angiogenesis. Current Biology, 2016, 26, 755-765.	3.9	57
65	Opposing effects of TIGAR- and RAC1-derived ROS on Wnt-driven proliferation in the mouse intestine. Genes and Development, 2016, 30, 52-63.	5.9	87
66	Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis. Cancer Research, 2016, 76, 724-735.	0.9	36
67	The SEARCHBreast Portal: A Virtual Bioresource to Facilitate the Sharing of Surplus Animal Materials Derived from Breast Cancer Studies. Open Journal of Bioresources, 2016, 3, .	1.5	0
68	Runx2 contributes to the regenerative potential of the mammary epithelium. Scientific Reports, 2015, 5, 15658.	3.3	30
69	SEARCHBreast Workshop Proceedings: 3D Modelling of Breast Cancer. ATLA Alternatives To Laboratory Animals, 2015, 43, 367-375.	1.0	7
70	Acetyl-CoA Synthetase 2 Promotes Acetate Utilization and Maintains Cancer Cell Growth under Metabolic Stress. Cancer Cell, 2015, 27, 57-71.	16.8	596
71	Fumarate induces redox-dependent senescence by modifying glutathione metabolism. Nature Communications, 2015, 6, 6001.	12.8	208
72	Limited Mitochondrial Permeabilization Causes DNA Damage and Genomic Instability in the Absence of Cell Death. Molecular Cell, 2015, 57, 860-872.	9.7	341

#	Article	IF	Citations
73	Frequent Infection of Human Cancer Xenografts with Murine Endogenous Retroviruses in Vivo. Viruses, 2015, 7, 2014-2029.	3.3	13
74	Acute Inhibition of MEK Suppresses Congenital Melanocytic Nevus Syndrome in a Murine Model Driven by Activated NRAS and Wnt Signaling. Journal of Investigative Dermatology, 2015, 135, 2093-2101.	0.7	19
75	Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartateÂbiosynthesis. Nature Cell Biology, 2015, 17, 1317-1326.	10.3	226
76	Annexin A8 Identifies a Subpopulation of Transiently Quiescent c-Kit Positive Luminal Progenitor Cells of the Ductal Mammary Epithelium. PLoS ONE, 2015, 10, e0119718.	2.5	13
77	Expression of RUNX1 Correlates with Poor Patient Prognosis in Triple Negative Breast Cancer. PLoS ONE, 2014, 9, e100759.	2.5	80
78	iRFP is a sensitive marker for cell number and tumor growth in high-throughput systems. Cell Cycle, 2014, 13, 220-226.	2.6	34
79	HIRA orchestrates a dynamic chromatin landscape in senescence and is required for suppression of neoplasia. Genes and Development, 2014, 28, 2712-2725.	5.9	128
80	RUNX2 in subtype specific breast cancer and mammary gland differentiation. DMM Disease Models and Mechanisms, 2014, 7, 525-34.	2.4	53
81	Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells. Cancer & Metabolism, 2013, 1, 12.	5.0	87
82	TIGAR Is Required for Efficient Intestinal Regeneration and Tumorigenesis. Developmental Cell, 2013, 25, 463-477.	7.0	154
83	Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature, 2013, 493, 542-546.	27.8	773
84	RUNX2 in mammary gland development and breast cancer. Journal of Cellular Physiology, 2013, 228, 1137-1142.	4.1	66
85	Wnt signaling potentiates nevogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 16009-16014.	7.1	61
86	Activated Mutant NRasQ61K Drives Aberrant Melanocyte Signaling, Survival, and Invasiveness via a Rac1-Dependent Mechanism. Journal of Investigative Dermatology, 2012, 132, 2610-2621.	0.7	55
87	N-WASP coordinates the delivery and F-actinâ€"mediated capture of MT1-MMP at invasive pseudopods. Journal of Cell Biology, 2012, 199, 527-544.	5.2	151
88	The right time, the right place: will targeting human cancer-associated mutations to the mouse provide the perfect preclinical model?. Current Opinion in Genetics and Development, 2012, 22, 28-35.	3.3	5
89	Tiam1-Rac Signaling Counteracts Eg5 during Bipolar Spindle Assembly to Facilitate Chromosome Congression. Current Biology, 2010, 20, 669-675.	3.9	51
90	Runx2 in normal tissues and cancer cells: A developing story. Blood Cells, Molecules, and Diseases, 2010, 45, 117-123.	1.4	81

#	Article	IF	Citations
91	Loss of RAF Kinase Inhibitor Protein Is a Frequent Event In Acute Myeloid Leukemia with a Monocytic Phenotype and Cooperates with Mutant RAS In Malignant Transformation. Blood, 2010, 116, 4185-4185.	1.4	5
92	A Novel Model of SCID-X1 Reconstitution Reveals Predisposition to Retrovirus-induced Lymphoma but No Evidence of Î³C Gene Oncogenicity. Molecular Therapy, 2009, 17, 1031-1038.	8.2	29
93	Runx1 promotes B-cell survival and lymphoma development. Blood Cells, Molecules, and Diseases, 2009, 43, 12-19.	1.4	47
94	Insertional Mutagenesis Reveals Progression Genes and Checkpoints in MYC/Runx2 Lymphomas. Cancer Research, 2007, 67, 5126-5133.	0.9	44
95	<i>Runx2</i> Disruption Promotes Immortalization and Confers Resistance to Oncogene-Induced Senescence in Primary Murine Fibroblasts. Cancer Research, 2007, 67, 11263-11271.	0.9	42
96	X-SCID transgene leukaemogenicity. Nature, 2006, 443, E5-E6.	27.8	144
97	Runx2 and MYC Collaborate in Lymphoma Development by Suppressing Apoptotic and Growth Arrest Pathways In vivo. Cancer Research, 2006, 66, 2195-2201.	0.9	98
98	The runx genes: gain or loss of function in cancer. Nature Reviews Cancer, 2005, 5, 376-387.	28.4	418
99	RUNX1 transformation of primary embryonic fibroblasts is revealed in the absence of p53. Oncogene, 2004, 23, 5476-5486.	5.9	49
100	The Runx genes as dominant oncogenes. Blood Cells, Molecules, and Diseases, 2003, 30, 194-200.	1.4	53
101	Enforced Expression of<i>Runx2</i>Perturbs T Cell Development at a Stage Coincident with Î²-Selection. Journal of Immunology, 2002, 169, 2866-2874.	0.8	71
102	Proviral insertion indicates a dominant oncogenic role for Runx1/AML-1 in T-cell lymphoma. Cancer Research, 2002, 62, 7181-5.	0.9	56
103	Runx2: A novel oncogenic effector revealed by in vivo complementation and retroviral tagging. Oncogene, 2001, 20, 295-302.	5.9	101
104	Selection for Loss of p53 Function in T-Cell Lymphomagenesis Is Alleviated by Moloney Murine Leukemia Virus Infection in myc Transgenic Mice. Journal of Virology, 2001, 75, 9790-9798.	3.4	12
105	Sensitivity to myc-induced apoptosis is retained in spontaneous and transplanted lymphomas of CD2-mycERTM mice. Oncogene, 2000, 19, 773-782.	5.9	41
106	A full-length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with MYC. Oncogene, 1999, 18, 7124-7134.	5.9	83
107	Tumours derived from HTLV-Itax transgenic mice are characterized by enhanced levels of apoptosis and oncogene expression. Journal of Pathology, 1998, 186, 209-214.	4.5	51